Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Masatoshi Kudo, Yusuke Kawamura, Kiyoshi Hasegawa, et al.
Liver Cancer (2021) Vol. 10, Iss. 3, pp. 181-223
Open Access | Times Cited: 493

Showing 1-25 of 493 citing articles:

Hepatocellular carcinoma
Arndt Vogel, Tim Meyer, Gonzalo Sapisochín, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1345-1362
Closed Access | Times Cited: 1345
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau, Joong‐Won Park, Richard S. Finn, et al.
The Lancet Oncology (2021) Vol. 23, Iss. 1, pp. 77-90
Closed Access | Times Cited: 840
Changing epidemiology of hepatocellular carcinoma in Asia
Chenhao Zhang, Yifei Cheng, Shu Zhang, et al.
Liver International (2022) Vol. 42, Iss. 9, pp. 2029-2041
Closed Access | Times Cited: 241
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)
Ning Lyu, Xun Wang, Jibin Li, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 5, pp. 468-480
Closed Access | Times Cited: 215
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 583-705
Open Access | Times Cited: 193
The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update
Ningyuan Wen, Yulong Cai, Fu‐Yu Li, et al.
BioScience Trends (2022) Vol. 16, Iss. 1, pp. 20-30
Open Access | Times Cited: 137
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept
Alessandro Vitale, Giuseppe Cabibbo, Massimo Iavarone, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 7, pp. e312-e322
Closed Access | Times Cited: 113
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Josep M. Llovet, Roser Pinyol, Mark Yarchoan, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 294-311
Closed Access | Times Cited: 106
Biomarkers for immunotherapy of hepatocellular carcinoma
Tim F. Greten, Augusto Villanueva, Firouzeh Korangy, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 780-798
Closed Access | Times Cited: 99
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, et al.
Liver Cancer (2022) Vol. 11, Iss. 4, pp. 354-367
Open Access | Times Cited: 90
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Korean Journal of Radiology (2022) Vol. 23, Iss. 12, pp. 1126-1126
Open Access | Times Cited: 90
A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights
Diyang Xie, Kai Zhu, Zhenggang Ren, et al.
HepatoBiliary Surgery and Nutrition (2023) Vol. 12, Iss. 2, pp. 216-228
Open Access | Times Cited: 90
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 797-809
Closed Access | Times Cited: 86
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Journal of Liver Cancer (2022) Vol. 23, Iss. 1, pp. 1-120
Open Access | Times Cited: 83
Breakthroughs in Hepatocellular Carcinoma Therapies
Amit G. Singal, Masatoshi Kudo, Jordi Bruix
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2135-2149
Open Access | Times Cited: 81
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, et al.
Liver Cancer (2023) Vol. 12, Iss. 4, pp. 321-338
Open Access | Times Cited: 68
Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives
Maxime Ronot, Victoria Chernyak, Adam M. Burgoyne, et al.
Radiology (2023) Vol. 307, Iss. 3
Closed Access | Times Cited: 54
Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy
Stergios A. Pοlyzos, Lampros Chrysavgis, Ilias D. Vachliotis, et al.
Seminars in Cancer Biology (2023) Vol. 93, pp. 20-35
Closed Access | Times Cited: 48
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, et al.
Liver Cancer (2023) Vol. 13, Iss. 1, pp. 99-112
Open Access | Times Cited: 45
Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal
Franco Trevisani, Alessandro Vitale, Masatoshi Kudo, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 4, pp. 661-669
Closed Access | Times Cited: 25
Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed Death-1 inhibitors
Renguo Guan, Nan Zhang, Min Deng, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 16
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Masatoshi Kudo, Zhenggang Ren, Yabing Guo, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 203-215
Closed Access | Times Cited: 13
Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma – The Changing Tides
Abdul Rehman Khan, Xuyong Wei, Xiao Xu
Journal of Hepatocellular Carcinoma (2021) Vol. Volume 8, pp. 1089-1115
Open Access | Times Cited: 77
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
Masatoshi Kudo
Liver Cancer (2021) Vol. 10, Iss. 6, pp. 539-544
Open Access | Times Cited: 69
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Masatoshi Kudo
Liver Cancer (2022) Vol. 11, Iss. 5, pp. 399-406
Open Access | Times Cited: 55
Page 1 - Next Page

Scroll to top